MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

Post author:
Post published:April 16, 2024
Post category:uncategorized

The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

mRNA COVID vaccines in pregnancy linked to lower risk of neonatal issues, study shows

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

Helpful Links

Subscribe To Us